BofA analyst Tazeen Ahmad raised the firm’s price target on Ocular Therapeutix (OCUL) to $27 from $24 and keeps a Buy rating on the shares. Comprehensive analyses from the Phase 3 SOL-1 trial provided important clarity on key questions following the topline readout, says the analyst, who thinks these data “strongly support the case for approval” and de-risk the diabetic retinopathy program.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCUL:
- OCUL: SOL-1 Phase 3 Data, Regulatory Strategy, and Durability Advantages Underpin Reaffirmed Buy Rating and $27 Target
- Ocular Therapeutix price target raised to $28 from $21 at Clear Street
- Axpaxli’s Superior SOL-1 Phase 3 Data Support Buy Rating and Constructive Outlook on Ocular Therapeutix
- OCUL: Strengthening Axpaxli Clinical Profile and Manageable Safety Support Buy Rating in Neovascular AMD
- Ocular Therapeutix Highlights Phase 3 AXPAXLI Trial Progress